Why Is MEDPACE HLDGS INC (MEDP) Stock Up Today?

MEDP stock rose 16.11% to $613.23 on July 23, driven by the company's second-quarter 2026 earnings report and guidance revisions. The stock opened with a 18.3% gap up from the previous close, reaching an intraday high of $677.90 before settling near $615.00. The move followed a strong performance in new business awards and an upward revision to full-year financial guidance.

What Happened

Medpace Holdings reported second-quarter 2026 results and filed an 8-K with the SEC on July 22. The company raised its full-year 2026 GAAP EPS guidance from $16.68 to $17.50 to $17.25 to $17.95, exceeding the $16.97 consensus estimate. It also increased its sales guidance from $2.755 billion to $2.855 billion to $2.805 billion to $2.885 billion, surpassing the $2.778 billion estimate. The company reported Q2 new business awards of $795.7 million, up 28.2% year-over-year, resulting in a net book-to-bill ratio of 1.13x. Additionally, Medpace repurchased 705,616 shares for $294.7 million during the quarter. The earnings call presentation was published on July 23, highlighting the company's performance and outlook.

What The Data Shows

The stock opened at $625.00 and traded as high as $677.90 before declining to a low of $609.53. Volume reached 0.3 million shares, 0.8 times the 3-month average. The stock has traded between $373.00 and $628.92 over the past 52 weeks. Over the last 8 sessions, it declined 0.4% from $535.07 to $532.95. The company has a market cap of $15.2 billion, a P/E ratio of 33.2, and a revenue growth rate of 24.2% trailing twelve months. Net margin is 17.2%, and beta is 1.15. Recent insider transactions include a $7.4 million sale by Ewald Stephen P on June 1. Congressional trades show Rep. David J. Taylor made three purchases between $1,001 and $15,000 between February 26 and May 15.

What To Watch

The company is scheduled to host a call on July 23 to discuss its second-quarter results. Investors may monitor coverage breadth and any further guidance updates.